Resources
BNET Resources
- sort by:
- Relevance
- Date
- Popularity
- Measuring Quality of Care for Prostate Cancer
- Prostate cancer is the most common solid malignancy diagnosed in American men. There is a need for valid measures for assessing quality of care for prostate cancer, and there is a need to understand how variations in quality of care affect treatment outcomes. This report summarizes the work "Prostate Cancer...
- White papers
- Detection of Prostate Cancer by Integration of Line-Scan Diffusion, T2-Mapping and T2-Weighted Magnetic Resonance Imaging; a Multichannel Statistical Classifier
- Prostate cancer is the most commonly diagnosed noncutaneous malignancy and the second-leading cause of death from cancer in American men.1 Over 40 000 American men are diagnosed with prostate cancer each year and cancer is found at autopsy in 30% of men at the age of 50.2 Evidence suggested that...
- White papers 2003-09-01
- CSPI: Bayer Falsely Claimed One A Day Vitamins Prevent Prostate Cancer
- Bayer has been threatened with a lawsuit by the Center for Science in the Public Interest over its claims that its One A Day vitamin product can somehow prevent prostate cancer. The CSPI claims Bayer's ads are false and deceptive because they claim that the selenium in One A Day...
- Blog posts 2009-06-20
Additional Resources
- US and Australian Biotechs Collaborate to Develop New Semen-Based Non-Invasive Prostate Cancer Test; Prostate Cancer Associated Biomarker Identified by Proteome Systems Just Days Prior to Prostate Cancer Awareness Month
- BOSTON -- Just days prior to Prostate Cancer Awareness Month (September 2006) a leading biotech team developing a semen-based prostate cancer test -- designed to improve on the accuracy of the prostate-specific antigen PSA test -- has identified a prostate cancer biomarker associated with Human Carcinoma-Antigen HCA. When present along...
- Research articles 2006-09-06
- Gillette Announces Prostate Cancer Awareness Initiative; Gillette Prostate Cancer Challenge Will Help Men and Their Families to Learn and Talk about Prostate Cancer Risks, Prevention and Detection
- BOSTON -- Gillette today announced the launch of the Gillette Prostate Cancer Challenge, a nationwide effort to raise awareness of the risks, symptoms and benefits of early detection of prostate cancer, the second leading cause of cancer deaths in American men. E[acute accent]Gillette is teaming with the National Prostate Cancer...
- Research articles 2006-02-17
- Medarex's Vaccine-Like Prostate Cancer Treatment Shows Great Promise
- The news from Mayo Clinic about the success of Medarex’ MEDX and Bristol-Myers Squibb’s BMY monoclonal antibody Ipilimumabcombination treatment on inoperable prostate cancer patients cannot be overlooked. The news might represent a breakthrough in prostate cancer treatment as Ipilimumab has demonstrated efficacy on the category of prostate cancer patients who...
- External links 2009-06-23
- Prostate Cancer Screening: A Decision Guide for Men With Medicare
- This paper provides details about prostate cancer screening. Prostate cancer is made up of cells that do not grow normally. The cells divide and create new cells that the body does not need, forming a mass of tissue called a tumor. These abnormal cells sometimes spread to other parts of...
- White papers 2003-06-01
- Herbal Supplement May Prevent Prostate Cancer
- Columbia University Medical Center has launched the first clinical trial of a possible herbal preventative for prostate cancer. The Phase I study will determine whether Zyflamend®, an herbal supplement commonly used as an anti-inflammatory, can prevent prostate cancer in patients with prostatic intraepithelial neoplasia PIN. PIN is a...
- Research articles 2004-09-20
- THE WHITE HOUSE: President announces historic prostate cancer research grants at Dept of Defense
- M2 PRESSWIRE-23 June 1998-THE WHITE HOUSE: Office of the Press Secretary -- President Clinton announces historic prostate cancer research grants at the Dept of Defense C1994-98 M2 COMMUNICATIONS LTD RDATE:200698 * Highlights the administration's ambitious agenda to fight prostate cancer Today, in his Father's...
- Research articles 1998-06-23
- Warnex Offers New Prostate Cancer Screening Service
- Warnex Inc. (TSX: WNX) today announced that its Medical Laboratories division has launched a new screening service for prostate cancer, the PCA3 assay. The Warnex PCA3 screening service for prostate cancer uses advanced PCR technology to detect mRNA from the prostate cancer gene 3 (PCA3). Warnex is the first laboratory...
- Research articles 2008-03-05
- Warnex Offers New Prostate Cancer Screening Service.
- LAVAL, QUEBEC, Mar 5, 2008 Marketwire via COMTEX -- Warnex Inc. (TSX:WNX) today announced that its Medical Laboratories division has launched a new screening service for prostate cancer, the PCA3 assay. The Warnex PCA3 screening service for prostate cancer uses advanced PCR technology to detect mRNA...
- Research articles 2008-03-05
- Proteome Systems Makes Breakthrough in Development of Semen-Based Prostate Cancer Test; Discovery of Prostate-Specific Biomarker Protein Enables Improved Specificity of Diagnosing Prostate Cancer Using Semen Samples
- BOSTON & SYDNEY, Australia -- Scientists at Proteome Systems (ASX:PXL), the globally recognized diagnostics development and drug discovery company, have made an important breakthrough in their quest for developing a new diagnostic test for prostate cancer. They have identified a prostate-specific glycoprotein that is linked to Human Carcinoma Antigen HCA....
- Research articles 2006-08-01
- PC-1 prostate cancer marker gene sequenced; Matritech's scientists, in collaboration with scientists at Johns Hopkins School of Medicine, are first to confirm sequence of PC-1, known to be strongly correlated with prostate tumors, and first to characteriz
- CAMBRIDGE, Mass.--HealthWire--June 26, 1995--Matritech Inc. (NASDAQ:NMPS, BSE:MPS), a biotechnology company developing clinical products based upon cancer-specific Nuclear Matrix Proteins, today announced that its scientists have confirmed the DNA sequence of PC-1, a prostate cancer-specific Nuclear Matrix Protein NMP.This discovery should accelerate the development of an improved prostate cancer diagnostic, as...
- Research articles 1995-06-26
- New Data Report Matritech's NMP48 Prostate Cancer Blood Test More Accurate than PSA; NMP48 Test Could Reduce Unnecessary Biopsies
- Business Editors and Health/Medical Writers NEWTON, Mass.--BW HealthWire--Dec. 10, 2001 A new blood test for the detection of prostate cancer developed by Matritech Inc. (NASDAQ: NMPS) correctly identified men with benign prostate disease BPH as negative for prostate cancer. These results are a significant improvement over the widely...
- Research articles 2001-12-10
- Nemours Center for Childhood Cancer Research Team at the Alfred I. DuPont Hospital for Children Identifies the Function of a Biomarker Present in Prostate Cancer Cells: New Insight into Therapeutic Benefit for Patients with Advanced Prostate Cancer
- WILMINGTON, Del. -- The research team at the Nemours Center for Childhood Cancer Research NCCCR, a newly established division of Nemours Biomedical Research at the Alfred I. duPont Hospital for Children has discovered that the biomarker called prostate specific membrane antigen PSMA, abundantly present in cancer cells of patients with...
- Research articles 2008-07-17
- Prostate Cancer Prevention Trial Terminated Early; Results to be Published Early in New England Journal of Medicine
- WASHINGTON, June 24 /U.S. Newswire/ -- National Institutes of Cancer NCI are announcing early termination of the Prostate Cancer Prevention Trial. The study examined whether an enzyme inhibitor, finasteride, can reduce the prevalence of prostate cancer among the study group. A New England Journal of Medicine article, "The Influence...
- Research articles 2003-06-24
- New Canadian Biotechnology Company Targets Advanced Prostate Cancer, Milestone Medica and Dr. Martin Gleave of the Prostate Centre at Vancouver General Hospital Partner to Advance Novel Therapeutic Research.
- VANCOUVER, Nov 15, 2000 Milestone Medica Corporation and Dr. Martin Gleave, a Professor of Surgery/Urology at the University of British Columbia and a researcher at The Prostate Centre at Vancouver General Hospital, have co-founded OncoGenex Technologies Inc. to advance the pre-clinical and clinical ...
- Research articles 2000-11-15
- European Prostate Cancer Therapeutics Market Supported by Enhanced Awareness
- LONDON -- Prostate cancer is currently the second leading cause of cancer-related death in Western Europe, with as many as half a million patients in Germany, the United Kingdom, Spain, Italy and France alone. An ageing male population and heightened awareness about the disease is boosting the market for prostate...
- Research articles 2008-04-07
- Congressional Leaders Applaud Safeway for Prostate Cancer Campaign
- WASHINGTON -- Safeway Inc. (NYSE:SWY) A bipartisan group of U.S. House and Senate Congressional leaders applauded Safeway and two prostate cancer research and advocacy groups for their efforts to raise funds and awareness of prostate cancer. Led by Senator Saxby Chambliss (R-GA) and Congressman Frank LoBiondo (R-NJ), lawmakers gathered on...
- Research articles 2005-06-15
- From Bulls to BASS: Theragenics Corporation® Extends Prostate Cancer Treatment Awareness Campaign to the Sport of Bass Fishing; Leading Prostate Cancer Treatment Device Provider Signs Champion BASS Angler to Educate Millions of Fans
- ATLANTA -- Following up on the success of its 2005 direct-to-consumer marketing campaign, Theragenics Corporation, a medical device company serving the prostate cancer and surgical markets (NYSE: TGX), announces the extension of its prostate cancer treatment awareness campaign from bull riding to the sport of bass fishing. Professional BASS angler...
- Research articles 2006-01-17
- << Previous
- page 1 of 1
- Next >>
